GBA1_hESC_GBA#1-/-_10.18.11
CEBe033-A-1
General
Cell Line |
|
| hPSCreg name | CEBe033-A-1 |
| Cite as: | CEBe033-A-1 (RRID:CVCL_QX50) |
| Alternative name(s) |
GBA1_hESC_GBA#1-/-_10.18.11
|
| Cell line type | Human embryonic stem cell (hESC) |
| Similar lines |
CEBe033-A (SA001) CEBe033-A-11 (SA001_WT_HGPRT_2) CEBe033-A-8 (SA001_KO_HGPRT_1) CEBe033-A-9 (SA001_KO_HGPRT_2) CEBe033-A-10 (SA001_WT_HGPRT_1) CEBe033-A-2 (SA001 Shank3 hetero1) CEBe033-A-3 (SA001 Shank3 Hetero2) CEBe033-A-4 (SA001 Shank3 Hetero3) CEBe033-A-5 (SA001 Shank3 Homo1) CEBe033-A-6 (SA001 Shank3 Homo2) CEBe033-A-7 (SA001 Shank3 Homo3) |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | F. Hoffmann-La Roche Ltd (ROCHE) |
| Owner | F. Hoffmann-La Roche Ltd (ROCHE) |
External Databases |
|
| BioSamples | SAMEA104132790 |
| Cellosaurus | CVCL_QX50 |
| Wikidata | Q54809126 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
X,Y 46
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA104132810 |
Ethics
Also have a look at the ethics information for the parental line
CEBe033-A
.
| Was the embryo established purely for research purposes? | Yes |
| Have both parents consented to the use of the embryo for ESC derivation? | Yes |
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Alternatives to consent are available? | Yes |
| Alternatives to consent | |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | EKBB Ethikkommisson beider Basel Hebelstrasse 53 4056 Basel |
| Approval number | R-FP-S-2-0006-0006 |
hESC Derivation
|
The source cell information can be found in the parental cell line
CEBe033-A.
|
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 19 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
X,Y, 46
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.